GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Petros Pharmaceuticals PTPI · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

-3.75%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

—

FY2018FY2025

Net income

$1.9m

FY2018FY2025

Free cash flow

−$6.7m

FY2018FY2025

Shareholders' equity

$2.9m

FY2018FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue—$5.1m$5.8m$6.0m$7.8m$9.6m$15.6m$14.1m
Research and development—$2.6m$2.4m$1.7m$1.8m$459,636——
Operating income−$4.6m−$17.7m−$13.6m−$19.9m−$18.0m−$17.3m−$19.3m−$7.7m
Net income$1.9m−$14.3m−$8.2m−$20.0m−$9.0m−$20.6m−$32.5m−$32.5m
Diluted earnings per share0.05-1.78-2.73-9.65-6.34-18.61-50.28-0.69

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assets$5.2m$10.6m$33.8m$32.4m$67.4m$69.9m$58.4m$66.9m
Cash and short-term investments$5.1m$3.7m$13.3m$9.4m$23.8m$17.1m$2.1m$2.8m
Total liabilities$2.3m$18.1m$21.3m$15.7m$31.8m$52.4m$50.3m$68.6m
Debt—$7.4m$8.3m$9.9m$405,018$7.8m$13.7m$47.2m
Shareholders' equity$2.9m−$7.5m$12.5m$16.7m$35.5m$17.5m$8.0m−$1.7m
Shares outstanding42m8m3m2m1m1m1m47m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations−$6.7m−$2.6m−$7.6m−$12.8m−$11.9m−$15.3m$2.5m$8.0m
Capital spending—−$24,587−$1——−$4,633−$71,540−$1.9m
Free cash flow−$6.7m−$2.6m−$7.6m−$12.8m−$11.9m−$15.3m$2.5m$6.1m
Dividends paid−$974.0m−$1.29bn−$556.7m—————

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue——————$725,403$1.6m
Operating income−$988,501−$1.0m−$391,486−$990,737−$1.8m−$1.5m−$9.1m−$2.3m
Net income−$955,625−$987,036−$336,506−$922,723$5.4m−$2.3m−$9.3m−$2.2m
Diluted earnings per share-0.02-0.02-0.01-0.020.13-0.05-1.16-0.28
Cash from operations———−$1.0m−$3.0m−$1.0m——
Total assets$3.5m$4.4m$5.2m$6.1m$7.4m$17.6m$10.6m$20.7m
Cash and short-term investments$3.5m$4.4m—$6.1m$7.3m$8.9m$3.7m$3.9m
Debt—————$7.2m$7.3m$7.2m
Shareholders' equity$700,894$1.8m$2.9m$3.4m$4.4m−$9.6m−$7.5m$3.1m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-38.5%-23.1%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings0.1-0.1-0.3-0.1-3.2-1.4
Price to sales—0.40.40.53.73.1

Share price return

Finished calendar years

202520242023202220212020
Return-98%-73%-37%-94%-9%-6%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 25-to-1 reverse split · 1 May 2025
  • 10-to-1 reverse split · 1 Dec 2022

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.